Dice therapeutics 10q
WebAnnual report which provides a comprehensive overview of the company for the past year. 10-K. Annual Filings. 0000950170-23-008119.pdf. 0000950170-23-008119.rtf. … WebWe design and develop innovative oral medicines against biologically validated targets in immunology for the treatment of chronic autoimmune and inflammatory diseases. We are developing a growing pipeline of high-impact oral therapeutic candidates. Our lead program targets the IL-17 cytokine for psoriasis and other IL-17 mediated diseases.
Dice therapeutics 10q
Did you know?
WebOct 13, 2024 · Find the latest SEC Filings data for DICE Therapeutics, Inc. Common Stock (DICE) at Nasdaq.com. WebDICE Therapeutics started at outperform with $60 stock price target at Evercore ISI. Oct. 11, 2024 at 6:16 a.m. ET by Tomi Kilgore.
WebMar 30, 2024 · Posted by ABMN Staff on Mar 30th, 2024. DICE Therapeutics, Inc. ( NASDAQ:DICE – Get Rating) Director Ra Capital Management, L.P. purchased 155,089 shares of the company’s stock in a transaction that occurred on Thursday, March 23rd. The shares were purchased at an average cost of $26.67 per share, with a total value of … WebDec 31, 2024 · You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on …
WebDICE Therapeutics Inc. SEC filings breakout by MarketWatch. View the DICE U.S. Securities and Exchange Commission reporting information. WebMar 28, 2024 · DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in ...
WebFORM 10-Q (M ar k O ne ) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 F or th e q u ar te r l y p e r i od e n d e d S e p te mb e r 30, 2024 O R ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
WebApr 11, 2024 · DICE Therapeutics, Inc. SEC Filing - Quarterly Report (10-Q) August 11, 2024 SEC Filings Thu, Aug. 11, 2024 DICE Therapeutics initiated at buy at Wainwright … edgelawnWebPioneers in small molecule drug development. Our mission is to become an industry leader in creating transformative small molecule medicines for autoimmune and inflammatory … congqianshuo youtubeWebMar 21, 2024 · About DICE Therapeutics, Inc. ... risks and uncertainties described under the heading “Risk Factors” in the Company’s quarterly report on Form 10-Q filed on November 12, 2024, and its other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by … edge le143 modular home by champion homesWebApr 1, 2024 · DICE Therapeutics Stock Performance. Shares of DICE opened at $28.67 on Friday. DICE Therapeutics has a 52-week low of $12.64 and a 52-week high of $45.99. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -13.40 and a beta of 0.71. The business's fifty day moving average is $29.47 and its 200-day moving average is … edge lazy loadingWebSep 30, 2024 · false Q3--12-31 0001645569 P2Y P2M P4Y P6Y1M6D P6Y1M6D P5Y6M P6Y1M6D P5Y6M P6Y1M6D 0.75 0.80 0.0074 0.0074 0.0042 0.0082 0.0110 0.0173 P9Y11M12D P9Y11M12D P5Y P6Y8M12D P5Y P6Y8M12 edge lawn maintenance greenville scWebJan 24, 2024 · Financials. According to the 10-Q SEC Filing, DICE Therapeutics had cash, cash equivalents and marketable securities of $266.6 million as of September 30, 2024. This was an okay amount of cash ... edge lawyers birmingham alWebMar 15, 2024 · R&D Expenses: Research and development expenses were $20.1 million and $62.6 million for the fourth quarter and full year ended December 31, 2024, respectively, as compared to $12.2 million and ... c- on gpa